Navigation Links
Pivotal Study Validates Roche's cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer
Date:2/24/2011

missed by the Pap test, underscoring the limitations of cervical cancer screening with the Pap test alone.

"Arming more clinicians with HPV testing that has HPV-16 and HPV-18 genotyping will bring us one step closer to eradicating cervical cancer," said Paul Brown, Head of Roche Molecular Systems. "Results of the ATHENA study underscore the potential for a state-of-the-art diagnostic test to specifically identify women at highest risk for cervical disease."

About the Roche ATHENA Clinical Trial

The Roche ATHENA study for the cobas HPV Test is the largest U.S.-based registration study for cervical cancer screening, including more than 47,000 women. The study is designed to answer current medical and scientific questions about the importance of testing for high-risk HPV genotypes in cervical cancer screening and to provide clinical information about the specific HPV genotypes that place women at highest risk for developing cervical cancer. Results show the cobas HPV Test is comparable to the current standard of testing. Results also demonstrated that 1 in 10 women, age 30-years and older, who tested positive for HPV - 16 and/or 18 by the cobas HPV Test had cervical pre-cancer, although their Pap test was normal.  

About the cobas HPV Test

As demonstrated in the ATHENA trial, Roche's cobas HPV Test is the only HPV test under investigation in the U.S. that simultaneously detects 12 high-risk HPV types (HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) as a pooled result, as well as HPV genotypes 16 and 18 individually. Roche launched the cobas HPV Test in countries that accept CE Mark in 2009. The test is currently under review and pending Pre-Market Approval (PMA) by the U.S. Food and Drug Administration (FDA). The test is not currently available in the United States.

About Human Papillomavirus and Cervical Cancer

Persistent infection with human p
'/>"/>

SOURCE Roche Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
2. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
3. Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial
4. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
5. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
8. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
9. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
10. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
(Date:12/17/2014)... 2014 Achim Noack has been named ... Group. In this position, Noack will assist Jerry Stoller, ... develop marketing strategy and supervise global marketing management and ... has tremendous knowledge and experience in the crop protection ... experience and innovative thinking will be a great asset ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 17, 2014  United Therapeutics Corporation (NASDAQ: ... well as changes to Martine Rothblatt , Ph.D,s ... United Therapeutics announced the promotion of ... Officer and David Zaccardelli , Pharm.D. to Executive ... these promotions, Dr. Rothblatt,s title will change from Chairman ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... 2011 Reportlinker.com announces that a new market research ... The Future of In Vitro and In ... The term in-vitro/in-vivo diagnostics (IV2D) ... and pathology (imaging), as well as new software ...
... YORK, Jan. 25, 2011 Reportlinker.com announces ... available in its catalogue: ... Implications of Emerging Reimbursement, Technological and Market ... http://www.reportlinker.com/p0365288/Future-US-In-Vitro-Diagnostics-Market-Strategic-Implications-of-Emerging-Reimbursement-Technological-and-Market-Trends-through-2018.html How will ...
... 23, 2011 An interdisciplinary team from Columbia University ... together with researchers from the University,s departments of Physics ... single-molecule interactions on very short time scales using nanoscale ... 23 in Nature Nanotechnology , they show how, ...
Cached Biology Technology:Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration 2Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration 3Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018 2Columbia University researchers use nanoscale transistors to study single-molecule interactions 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... , Aug. 20, 2013  Today BluStor PMC, Inc. ... platform that protects the full stream of mobile ... vision for what,s possible using BluStor, the company ... at: http://www.blustor.com/whatspossible.php . (Logo:   ...
... fashion and look set to become big business in the baking ... by some chickens is prettier and some say tastier and cleaner-breaking ... from The University of Nottingham, we know what caused the eggs ... four-year research project just published in the journal, PLOS ONE ...
... of Iowa researchers have discovered what causes the lethal ... infection of heart valves that kills approximately 20,000 Americans ... culprits are superantigens -- toxins produced in large quantities ... disrupt the immune system, turning it from friend to ...
Cached Biology News:BluStor Introduces the World's First Platform to Protect the Full Stream of Mobile Security: Device, User, And Data 2Unscrambling the genetics of the chicken's 'blue' egg 2Bacterial toxins cause deadly heart disease 2